APA (7th ed.) Citation

Kim, T. W., Burris, H. A., de Miguel Luken, M. J., Pishvaian, M. J., Bang, Y., Gordon, M., . . . Siu, L. L. (2022). First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical cancer research, 28(16), 3452. https://doi.org/10.1158/1078-0432.CCR-21-4020

Chicago Style (17th ed.) Citation

Kim, Tae Won, et al. "First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors." Clinical Cancer Research 28, no. 16 (2022): 3452. https://doi.org/10.1158/1078-0432.CCR-21-4020.

MLA (9th ed.) Citation

Kim, Tae Won, et al. "First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors." Clinical Cancer Research, vol. 28, no. 16, 2022, p. 3452, https://doi.org/10.1158/1078-0432.CCR-21-4020.